Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164


Association between acquired uniparental disomy and homozygous mutations and HER2/ER/PR status in breast cancer.

Tuna M, Smid M, Zhu D, Martens JW, Amos CI.

PLoS One. 2010 Nov 30;5(11):e15094. doi: 10.1371/journal.pone.0015094.


Prognostic value of acquired uniparental disomy (aUPD) in primary breast cancer.

Tuna M, Smid M, Martens JW, Foekens JA.

Breast Cancer Res Treat. 2012 Feb;132(1):189-96. doi: 10.1007/s10549-011-1579-y. Epub 2011 May 21.


Prognostic relevance of acquired uniparental disomy in serous ovarian cancer.

Tuna M, Ju Z, Smid M, Amos CI, Mills GB.

Mol Cancer. 2015 Feb 3;14:29. doi: 10.1186/s12943-015-0289-1.


Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.

Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez-MacGregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam F.

Am J Clin Pathol. 2015 Nov;144(5):713-21. doi: 10.1309/AJCPWDEQYCYC92JQ.


Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.

Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH, Kim SW, Lee JE, Nam SJ.

BMC Cancer. 2015 Mar 18;15:138. doi: 10.1186/s12885-015-1121-4.


High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.

Staaf J, Jönsson G, Ringnér M, Vallon-Christersson J, Grabau D, Arason A, Gunnarsson H, Agnarsson BA, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A.

Breast Cancer Res. 2010;12(3):R25. doi: 10.1186/bcr2568. Epub 2010 May 6.


Oncoprotein HCCR-1 expression in breast cancer is well correlated with known breast cancer prognostic factors including the HER2 overexpression, p53 mutation, and ER/PR status.

Ha SA, Lee YS, Shin SM, Kim HK, Kim S, Namkoong H, Kim HJ, Jung SM, Lee YS, Chung YJ, Jung SS, Kim JW.

BMC Cancer. 2009 Feb 11;9:51. doi: 10.1186/1471-2407-9-51.


Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

J Surg Res. 2007 Nov;143(1):109-18.


NFIB is a potential target for estrogen receptor-negative breast cancers.

Moon HG, Hwang KT, Kim JA, Kim HS, Lee MJ, Jung EM, Ko E, Han W, Noh DY.

Mol Oncol. 2011 Dec;5(6):538-44. doi: 10.1016/j.molonc.2011.08.002. Epub 2011 Aug 8.


Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.

Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M, Amano S, Kaminishi M, Yamada T, Takubo K.

Oncol Rep. 2008 Mar;19(3):651-6.


Expression and mutational analysis of GATA3 in Malaysian breast carcinomas.

Bong PN, Zakaria Z, Muhammad R, Abdullah N, Ibrahim N, Emran NA, Syed Hussain SN.

Malays J Pathol. 2010 Dec;32(2):117-22.


Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.

Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, Shapiro DH.

Mod Pathol. 2002 Aug;15(8):853-61.


An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer.

McCleland ML, Adler AS, Shang Y, Hunsaker T, Truong T, Peterson D, Torres E, Li L, Haley B, Stephan JP, Belvin M, Hatzivassiliou G, Blackwood EM, Corson L, Evangelista M, Zha J, Firestein R.

Cancer Res. 2012 Nov 15;72(22):5812-23. doi: 10.1158/0008-5472.CAN-12-1098. Epub 2012 Nov 8.


Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ.

J Natl Cancer Inst. 2003 Jan 15;95(2):142-53.


Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.

Del Casar JM, Martín A, García C, Corte MD, Alvarez A, Junquera S, González LO, Bongera M, García-Muñiz JL, Allende MT, Vizoso F.

Eur J Obstet Gynecol Reprod Biol. 2008 Dec;141(2):147-52. doi: 10.1016/j.ejogrb.2008.07.021. Epub 2008 Sep 2.


Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.

Bauer K, Parise C, Caggiano V.

BMC Cancer. 2010 May 21;10:228. doi: 10.1186/1471-2407-10-228.


Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil.

Carvalho FM, Bacchi LM, Pincerato KM, Van de Rijn M, Bacchi CE.

BMC Womens Health. 2014 Aug 29;14:102. doi: 10.1186/1472-6874-14-102.


Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.

Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.

Cancer Chemother Pharmacol. 2012 Feb;69(2):533-46. doi: 10.1007/s00280-011-1730-9. Epub 2011 Sep 8.


Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.

Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L.

Cancer Res. 2010 Nov 1;70(21):8852-62. doi: 10.1158/0008-5472.CAN-10-1039. Epub 2010 Oct 19.

Supplemental Content

Support Center